

[953]

4. The recent development of an Intranasal vaccine will be a safe and effective vaccine that can prevent COVID infection.

Elaborate.

Bharat biotech's Intranasal vaccine have been recently given emergency ^{use} approval for heterologous booster to adults more than 18 years. Already primary vaccination to adults was given emergency approval.

Advantages of the Intranasal vaccine

1. Intranasal vaccine, prevents the virus at the point of entry itself
2. It is far more easier to administer

Trials conducted.

Heterologous booster vaccine - trials are conducted on. Participants already immunised with covaxins covishield.

Concerns

The vaccine is test only on lines of safety and Immunogenicity and not on efficacy

Immunogenicity does not automatically translate to efficacy. Also the vaccine does not have viral vector, due address New variants

Challenges

unlike, earlier vaccines, ~~there is~~ a challenge in conducting trials in humans, as the

1. New variants are emerging which are highly evasive
2. Natural infections - owing to already immunised one eg. omicron

Human challenge studies needed.

Earlier studies with respect to Oxford vaccine - adeno viral vector showed only minority developed antibody immune response and its efficacy was not strong enough

Way forward

Already demand for vaccines are declining due to reduction in covid cases. unless efficacy as a factor is considered, test, full potential of vaccine may not be ~~achieved~~ realised.